Soren Bertelsen

Director of Process Optimisation

Novo Nordisk

Søren Bertelsen holds a master in medicinal chemistry from Aarhus University and a phd in organic chemistry from the same university (awarded with the AUFF phd prize of 2010). After a postdoc at Skejby University Hospital, doing ex vivo chemical experiments and analytic development, he got hired at Novo Nordisk in 2010. Working as a process chemist in the early research laboratories, Sørens tasks included process optimizations and greenification of the choices of reagents and conditions. As a process chemist he became acquainted with DoE and later Bayesian Optimization as a modern way to ensure fast learning and modelling of the parameter-space for chemistry and related fields. In 2020, he transferred to a role in Data Science at Novo Nordisk to further focus on development and sharing of tools for generalized process optimization. Currently, Søren is Director for Process Optimization, working on making robots for autonomous process development. Among others, we have build robots for closed-loop optimization of chemical reactions, ELISA- and LOCI-assays and HPLC-gradients.

Alexander Hillisch

Head of Global Computational Drug Design

UCB

Emilie Louvet

Clinical Information Science Director

AstraZeneca

I lead the Early oncology and NLP Oncology Information Practice team. The team deliver competitive intelligence data to enable Early Oncology Portfolio progression and drug development milestones investments decisions from Candidate Drug to Ph3ID, clinical design and clinical development plans via NLP& AI.

Cathrin Pautsch

Senior Scientist Data & Analytics

Roche

Cathrin strives to catalyze digitalization at Roche to accelerate data-driven drug discovery. She is the product owner of a synthesis planning automation (SPA) platform that leverages machine learning for predicting new synthetic routes for chemical compounds.

Andrew Buchanan

Principal Scientist (ML/Biologics)

AstraZeneca

An experienced team leader and inspiring scientist with an excellent track record of leading innovative drug discovery projects and related technologies. As a leader, member or mentor of teams Andrew has delivered more than 20 CD’s of which three are launched products benefiting patients. Andrew have over 20 years of successful cross-functional and global matrix-team leadership across BioPharm (R&I, CVRM, Neuro, ID) and Onc. With colleagues he has published over 35 original manuscripts and patents.

 

Giovanna Lalli

Director of Scientific Affairs

UK Dementia Research Institute HQ

Clay Schwabe

VP, Business Development

Pria Healthcare